1057 related articles for article (PubMed ID: 33686753)
1. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
[TBL] [Abstract][Full Text] [Related]
2. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
[TBL] [Abstract][Full Text] [Related]
3. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Inoue K; Masuda N; Iwata H; Takahashi M; Ito Y; Miyoshi Y; Nakayama T; Mukai H; van der Walt JS; Mori J; Sakaguchi S; Kawaguchi T; Tanizawa Y; Llombart-Cussac A; Sledge GW; Toi M
Breast Cancer; 2021 Sep; 28(5):1038-1050. PubMed ID: 33797023
[TBL] [Abstract][Full Text] [Related]
4. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
5. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
6. Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Toi M; Huang CS; Im YH; Sohn J; Zhang W; Sakaguchi S; Haddad N; van Hal G; Sledge GW
Cancer Sci; 2023 Jan; 114(1):221-226. PubMed ID: 36168844
[TBL] [Abstract][Full Text] [Related]
7. MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR
Neven P; Johnston SRD; Toi M; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Haddad N; Hurt KC; Llombart-Cussac A; Sledge GW
Clin Cancer Res; 2021 Nov; 27(21):5801-5809. PubMed ID: 34376533
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Goetz MP; Martin M; Tokunaga E; Park IH; Huober J; Toi M; Stoffregen C; Shekarriz S; Andre V; Gainford MC; Price GL; Johnston S
Oncologist; 2020 Sep; 25(9):e1346-e1354. PubMed ID: 32536013
[TBL] [Abstract][Full Text] [Related]
9. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Takahashi M; Tokunaga E; Mori J; Tanizawa Y; van der Walt JS; Kawaguchi T; Goetz MP; Toi M
Breast Cancer; 2022 Jan; 29(1):174-184. PubMed ID: 34661821
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Goetz MP; Okera M; Wildiers H; Campone M; Grischke EM; Manso L; André VAM; Chouaki N; San Antonio B; Toi M; Sledge GW
Breast Cancer Res Treat; 2021 Apr; 186(2):417-428. PubMed ID: 33392835
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
[TBL] [Abstract][Full Text] [Related]
12. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
13. Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
Goetz MP; Hamilton EP; Campone M; Hurvitz SA; Cortes J; Johnston S; Llombart-Cussac A; Kaufman PA; Toi M; Jerusalem G; Graham H; Wang H; Jansen VM; Litchfield LM; Martin M
Clin Cancer Res; 2024 May; 30(10):2233-2244. PubMed ID: 37889120
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz MP; Toi M; Huober J; Sohn J; Trédan O; Park IH; Campone M; Chen SC; Manso LM; Paluch-Shimon S; Freedman OC; O'Shaughnessy J; Pivot X; Tolaney SM; Hurvitz S; Llombart-Cussac A; André V; Saha A; van Hal G; Shahir A; Iwata H; Johnston SRD
Ann Oncol; 2024 May; ():. PubMed ID: 38729566
[TBL] [Abstract][Full Text] [Related]
15. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Kaufman PA; Toi M; Neven P; Sohn J; Grischke EM; Andre V; Stoffregen C; Shekarriz S; Price GL; Carter GC; Sledge GW
Oncologist; 2020 Feb; 25(2):e243-e251. PubMed ID: 32043763
[TBL] [Abstract][Full Text] [Related]
16. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Rugo HS; Huober J; García-Sáenz JA; Masuda N; Sohn JH; Andre VAM; Barriga S; Cox J; Goetz M
Oncologist; 2021 Jan; 26(1):e53-e65. PubMed ID: 32955138
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Tolaney SM; Toi M; Neven P; Sohn J; Grischke EM; Llombart-Cussac A; Soliman H; Wang H; Wijayawardana S; Jansen VM; Litchfield LM; Sledge GW
Clin Cancer Res; 2022 Apr; 28(8):1500-1506. PubMed ID: 35121623
[TBL] [Abstract][Full Text] [Related]
18. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR
Dickler MN; Tolaney SM; Rugo HS; Cortés J; Diéras V; Patt D; Wildiers H; Hudis CA; O'Shaughnessy J; Zamora E; Yardley DA; Frenzel M; Koustenis A; Baselga J
Clin Cancer Res; 2017 Sep; 23(17):5218-5224. PubMed ID: 28533223
[No Abstract] [Full Text] [Related]
19. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
20. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study.
Zhang QY; Sun T; Yin YM; Li HP; Yan M; Tong ZS; Oppermann CP; Liu YP; Costa R; Li M; Cheng Y; Ouyang QC; Chen X; Liao N; Wu XH; Wang XJ; Feng JF; Hegg R; Kanakasetty GB; Coccia-Portugal MA; Han RB; Lu Y; Chi HD; Jiang ZF; Hu XC
Ther Adv Med Oncol; 2020; 12():1758835920963925. PubMed ID: 33149768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]